Synthesis of novel heterocyclic compounds containing pyrimidine nucleus using the Biginelli reaction: Antiproliferative activity and docking studies
Özet
In a single reaction step, pyrimidine derivatives (4a-p) were synthesized from the triple reaction of aromatic aldehydes (1), ethyl cyanoacetate (2), and some guanyl hydrazone derivatives (3a-n). These compounds were tested as in vitro against two types of cancerous cell lines, namely, a human colon cancerous cell line (DLD-1) and a human breast cancerous cell line (MDA-MB-231). According to the obtained results, nearly all the compounds have cytotoxic activity in the tested cell lines. Especially, the compounds 4j, 4k, and 4n had a significant effect against DLD-1. Furthermore, compounds 4g, 4m, and 4o exhibited lower IC50 values compared to other synthesized compounds against MDA-MB-231. We hope that these compounds can be improved as anticancer agents in the future. Molecular docking was performed according to both topoisomerase I and N-acetyltransferase 1 proteins to examine theoretically the binding mode and site of pyrimidine compounds having the best activity. © 2020 Wiley Periodicals, Inc.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Çağlar Yavuz, Sevtap | |
| dc.contributor.author | Akkoç, Senem | |
| dc.contributor.author | Türkmenoğlu, Burçin | |
| dc.contributor.author | Sarıpınar, Emin | |
| dc.date.accessioned | 2026-10-18T20:28:41.595500051Z | |
| dc.date.available | 2026-10-18T20:28:41.595500051Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | In a single reaction step, pyrimidine derivatives (4a-p) were synthesized from the triple reaction of aromatic aldehydes (1), ethyl cyanoacetate (2), and some guanyl hydrazone derivatives (3a-n). These compounds were tested as in vitro against two types of cancerous cell lines, namely, a human colon cancerous cell line (DLD-1) and a human breast cancerous cell line (MDA-MB-231). According to the obtained results, nearly all the compounds have cytotoxic activity in the tested cell lines. Especially, the compounds 4j, 4k, and 4n had a significant effect against DLD-1. Furthermore, compounds 4g, 4m, and 4o exhibited lower IC50 values compared to other synthesized compounds against MDA-MB-231. We hope that these compounds can be improved as anticancer agents in the future. Molecular docking was performed according to both topoisomerase I and N-acetyltransferase 1 proteins to examine theoretically the binding mode and site of pyrimidine compounds having the best activity. © 2020 Wiley Periodicals, Inc. | |
| dc.description.sponsorship | Funding text 1: This work was financially supported by the Research Fund of Erciyes Üniversitesi [FDK‐2016‐6664]. We would like to thank the Genome and Stem Cell Center (GENKÖK) for their assistance. We are also thankful to Prof Dr Mustafa Çetin for donating two positive control drugs. ; Funding text 2: Research Fund of Erciyes University, Grant/Award Number: FDK‐2016‐6664 Funding information ; Funding text 3: This work was financially supported by the Research Fund of Erciyes Üniversitesi [FDK-2016-6664]. We would like to thank the Genome and Stem Cell Center (GENKÖK) for their assistance. We are also thankful to Prof Dr Mustafa Çetin for donating two positive control drugs. | |
| dc.identifier.doi | 10.1002/jhet.3978 | |
| dc.identifier.eissn | 1943-5193 | |
| dc.identifier.endpage | 2627 | |
| dc.identifier.issn | 0022-152X | |
| dc.identifier.issue | 6 | |
| dc.identifier.scopus | 2-s2.0-85084668055 | |
| dc.identifier.startpage | 2615 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/13890 | |
| dc.identifier.volume | 57 | |
| dc.identifier.wos | WOS:000523636700001 | |
| dc.language.iso | en | |
| dc.publisher | HeteroCorporation | |
| dc.relation.ispartof | Journal of Heterocyclic Chemistry | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | 2 [2 [(2 chloro 6 fluorophenyl)methylidene] hydrazino] 4 hydroxy 6 phenylpyrimidine 5 carbonitrile | |
| dc.subject | 2 [2 [(2,4 dimethoxyphenyl)methylidene]hydrazino] 4 hydroxy 6 phenyl 1,6 dihydropyrimidine 5 carbonitrile | |
| dc.subject | 4 hydroxy 2 [2 [1 (4 methoxyphenyl)ethylidene] hydrazino] 6 phenylpyrimidine 5 carbonitrile | |
| dc.subject | 4 hydroxy 6 (4 methylphenyl) 2 [2 [(4 methyl phenyl) methylidene]hydrazino]pyrimidine 5 carbonitrile | |
| dc.subject | 4 hydroxy 6 phenyl 2 [2 (1 phenylethylidene) hydrazino]pyrimidine 5 carbonitrile | |
| dc.subject | heterocyclic compound | |
| dc.subject | n [[4 [(5 cyano 4 hydroxy 6 phenylpyrimidin 2 yl) hydrazono]methyl]phenyl]acetamide | |
| dc.subject | pyrimidine derivative | |
| dc.subject | unclassified drug | |
| dc.subject | antiproliferative activity | |
| dc.subject | Article | |
| dc.subject | Biginelli reaction | |
| dc.subject | controlled study | |
| dc.subject | cytotoxicity | |
| dc.subject | DLD-1 cell line | |
| dc.subject | drug synthesis | |
| dc.subject | human | |
| dc.subject | human cell | |
| dc.subject | IC50 | |
| dc.subject | MDA-MB-231 cell line | |
| dc.subject | molecular docking | |
| dc.title | Synthesis of novel heterocyclic compounds containing pyrimidine nucleus using the Biginelli reaction: Antiproliferative activity and docking studies | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 21 | |
| rdl.citation.wos | 20 | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) | |
| rdl.wos.index | Index Chemicus (IC) |
